Insider Transactions in Q4 2020 at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2020
|
Charles Conway Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,361
-15.75%
|
$122,490
$90.14 P/Share
|
|
Nov 25
2020
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+25.78%
|
-
|
|
Nov 25
2020
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,965
-29.32%
|
$446,850
$90.14 P/Share
|
|
Nov 25
2020
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,950
+39.27%
|
-
|
|
Nov 25
2020
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,678
-20.41%
|
$151,020
$90.14 P/Share
|
|
Nov 25
2020
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+31.04%
|
-
|
|
Nov 25
2020
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,701
-23.02%
|
$153,090
$90.14 P/Share
|
|
Nov 25
2020
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+33.67%
|
-
|
|
Nov 25
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,245
-26.18%
|
$112,050
$90.14 P/Share
|
|
Nov 25
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+38.68%
|
-
|
|
Nov 25
2020
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-29.34%
|
$137,790
$90.14 P/Share
|
|
Nov 25
2020
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,375
+39.27%
|
-
|
|
Nov 25
2020
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-23.76%
|
$43,200
$90.14 P/Share
|
|
Nov 25
2020
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+38.23%
|
-
|
|
Nov 23
2020
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
5,000
+0.2%
|
$445,000
$89.55 P/Share
|
|
Nov 02
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Open market or private sale
|
Direct |
30,000
-59.02%
|
$2,280,000
$76.91 P/Share
|
|
Nov 02
2020
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+48.58%
|
$1,500,000
$50.72 P/Share
|
|
Oct 23
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
10,403
-0.2%
|
$821,837
$79.42 P/Share
|
|
Oct 22
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
24,566
-0.48%
|
$1,940,714
$79.65 P/Share
|
|
Oct 19
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
4,554
-0.18%
|
$355,212
$78.98 P/Share
|
|
Oct 16
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
3,748
-0.14%
|
$292,344
$78.88 P/Share
|
|
Oct 12
2020
|
Gregory Bailey |
SELL
Open market or private sale
|
Direct |
6,729
-0.26%
|
$524,862
$78.87 P/Share
|
|
Oct 08
2020
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Open market or private sale
|
Direct |
23,500
-43.94%
|
$1,786,000
$76.49 P/Share
|
|
Oct 08
2020
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
23,500
+46.41%
|
$211,500
$9.29 P/Share
|